Lennart Roesner

Dr. Lennart Roesner


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
TWThomas Werfel
Thomas Werfel
AHAnnice Heratizadeh
Annice Heratizadeh
MNMargarete Niebuhr
Margarete Niebuhr
AKAlexander Kapp
Alexander Kapp
LRLennart Roesner
Lennart Roesner
JHJens M. Hohlfeld
Jens M. Hohlfeld

8 September 2022 in Allergy
Verified
Journal Article
Open access
BZBowen Zhang
Bowen Zhang
LRLennart Roesner
Lennart Roesner
STStephan Traidl
Stephan Traidl
VKValerie A. C. M. Koeken
Valerie A. C. M. Koeken
CXCheng‐Jian Xu
Cheng‐Jian Xu
YLYang Li
Yang Li
Background: Understanding the complex orchestrated inflammation in atopic dermatitis (AD), one of the most common chronic inflammatory diseases worldwide, is essential for therapeutic approaches. However, a comparative analysis on the single‐cell level of the inflammation signatures correlated with the severity is missing so far.Methods: We applied single‐cell RNA and T‐cell receptor (TCR) sequencing on immune cells enriched from skin biopsies and matched blood samples of AD in comparison with psoriasis (PS) patients.Results: Clonally propagated skin‐derived T cells showed disease‐specific TCR motifs shared between patients which was more pronounced in PS compared to AD. The disease‐specific T‐cell clusters were mostly of a Th2/Th22 sub‐population in AD and Th17/Tc17 in PS, and their numbers were associated with severity scores in both diseases. Herein, we provide for the first time a list that associates cell type‐specific gene expression with the severity of the two most common chronic inflammatory skin diseases. Investigating the cell signatures in the patients´ PBMCs and skin stromal cells, a systemic involvement of type‐3 inflammation was clearly detectable in PS circulating cells, while in AD inflammatory signatures were most pronounced in fibroblasts, pericytes, and keratinocytes. Compositional and functional analyses of myeloid cells revealed the activation of antiviral responses in macrophages in association with disease severity in both diseases.Conclusion: Different disease‐driving cell types and subtypes which contribute to the hallmarks of type‐2 and type‐3 inflammatory signatures and are associated with disease activities could be identified by single‐cell RNA‐seq and TCR‐seq in AD and PS.

1 June 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
JSJenny Seltmann
Jenny Seltmann
LRLennart Roesner
Lennart Roesner
FHFriedrich-Wilhelm von Hesler
Friedrich-Wilhelm von Hesler
MWMiriam Wittmann
Miriam Wittmann
TWThomas Werfel
Thomas Werfel
NoIL-33 is a member of the IL-1 family of cytokines that is constitutively expressed in healthy skin and was found to be increased in the skin of patients with atopic dermatitis (AD). Because it can be released after tissue damage or physical stress including scratching of the skin,1 it has been classified as an alarmin concerned with alerting the immune system.2 It enhances TH2 responses by inducing IL-5 and IL-13 as well as TH1 responses via upregulation of IFN-γ. Keratinocytes are known producer cells of IL-33 and also express the receptor complex consisting of ST2 and IL-1RAcP on their surface. The aim of this study was to investigate the effect of IL-33 on keratinocytes, skin biopsies, and living skin equivalents with regard to the regulation of the skin barrier molecule filaggrin (FLG)

12 April 2021 in Allergy
Verified
Journal Article
Open access
PDF file
STStephan Traidl
Stephan Traidl
LRLennart Roesner
Lennart Roesner
JZJana Zeitvogel
Jana Zeitvogel
TWThomas Werfel
Thomas Werfel
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases leading to pruritic skin lesions. A subset of AD patients exhibits a disseminated severe HSV infection called eczema herpeticum (EH) that can cause life‐threatening complications. This review gives an overview of the clinical picture, and characteristics of the patients as well as the diagnosis and therapy of EH. A special focus lies on the pathophysiological hallmarks identified so far that predispose for EH. This aspect covers genetic aberrations, immunological changes, and environmental influences displaying a complex multifactorial situation, which is not completely understood. Type 2 skewing of virus‐specific T cells in ADEH+ patients has been implicated in immune profile abnormalities, along with impaired functions of dendritic cells and natural killer cells. Furthermore, aberrations in interferon pathway‐related genes such as IFNG and IFNGR1 have been identified to increase the risk of EH. IL‐4, IL‐25, and thymic stromal lymphopoietin (TSLP) are overexpressed in EH, whereas antimicrobial peptides like human β‐defensins and LL‐37 are reduced. Concerning the epidermal barrier, single nucleotide polymorphisms (SNPs) in skin barrier proteins such as filaggrin were identified in ADEH+ patients. A dysbalance of the skin microbiome also contributes to EH due to an increase of Staphylococcus aureus, which provides a supporting role to the viral infection via secreted toxins such as α‐toxin. The risk of EH is reduced in AD patients treated with dupilumab. Further research is needed to identify and specifically target risk factors for EH in AD patients.

30 July 2015 in Allergy
Verified
Journal Article
Closed access
PDF file
LRLennart Roesner
Lennart Roesner
SFS. Floess
S. Floess
TWT. Witte
T. Witte
SOS. Olek
S. Olek
JHJ. Huehn
J. Huehn
TWT. Werfel
T. Werfel

30 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AFAnissa Fries
Anissa Fries
FSFanny Saidoune
Fanny Saidoune
FKFrançois Kuonen
François Kuonen
IDIsabelle Dupanloup
Isabelle Dupanloup
NFNadine Fournier
Nadine Fournier
MGMichel Gilliet
Michel Gilliet
Interleukin (IL)-26 is a TH17 cytokine with known antimicrobial and pro-inflammatory functions. However, the precise role of IL-26 in the context of pathogenic TH17 responses is unknown. Here we identify a population of blood TH17 intermediates that produce high levels of IL-26 and differentiate into IL-17A-producing TH17 cells upon TGF-β1 exposure. By combining single cell RNA sequencing, TCR sequencing and spatial transcriptomics we show that this process occurs in psoriatic skin. In fact, IL-26+ TH17 intermediates infiltrating psoriatic skin induce TGF-β1 expression in basal keratinocytes and thereby promote their own differentiation into IL-17A-producing cells. Thus, our study identifies IL-26-producing cells as an early differentiation stage of TH17 cells that infiltrates psoriatic skin and controls its own maturation into IL17A-producing TH17 cells, via epithelial crosstalk involving paracrine production of TGF-β1.